Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.2.0.727
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash $ 126,515 $ 44,411
Money market funds 1,124,064 213,699
Advances on research and development contract services 232,255 231,177
Prepaid expenses and other current assets 42,162 50,012
Total current assets 1,524,996 539,299
Total assets 1,524,996 539,299
Current liabilities:    
Accounts payable and accrued expenses 78,028 122,534
Research and development contract liabilities, including $81,250 and $18,436 to a related party at June 30, 2015 and December 31, 2014, respectively $ 120,157 58,186
Due to Chairman and major stockholder   92,717
Total current liabilities $ 198,185 $ 273,437
Commitments and contingencies    
Stockholders' equity:    
Series A convertible preferred stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 175,000 shares authorized, issued and outstanding at June 30, 2015; aggregate redemption value of $8,750,000; liquidation preference based on assumed conversion into common shares; 2,187,500 shares of common stock issuable upon conversion $ 1,750,000  
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 46,875,814 shares and 45,483,097 shares at June 30, 2015 and December 31, 2014, respectively 4,687 $ 4,548
Additional paid-in capital 16,748,855 15,979,475
Accumulated deficit (17,176,731) (15,718,161)
Total stockholders' equity 1,326,811 265,862
Total liabilities and stockholders' equity $ 1,524,996 $ 539,299